$CWBR CohBar, Inc. (NASDAQ:CWBR): Navigating the Challenges of a Biotechnology Startup https://beyondspx.com/article/cohbar-cwbr-a-promising-biotechnology-company-navigating-the-path-to-potential-breakthroughs
$CWBR CohBar (CWBR): A Promising Biotechnology Company Navigating the Path to Potential Breakthroughs https://beyondspx.com/article/cohbar-cwbr-a-promising-biotechnology-company-navigating-the-path-to-potential-breakthroughs
$CWBR CohBar, Inc. (NASDAQ:CWBR): Navigating the Challenges of a Biotechnology Startup http://beyondspx.com/2024/08/02/cohbar-inc-nasdaqcwbr-navigating-the-challenges-of-a-biotechnology-startup/
$HURA & TuHura 🆚 $CWBR & Morphogenesis Merger 🤔📈
If you ask me Kintara’s merger with TuHURA is poised for success 🚀🚀🚀due to their shared focus on cancer treatments and robust $31 million financing. This aligns them better for growth, unlike the failed CohBar-Morphogenesis merger, which struggled with strategic mismatches and financial uncertainty. And let’s don’t forget Congresswoman Laurel Lee’s purchase of corporate securities of $100,001 to $250,000.
💰💰💰🤑🧪🧪✅
Sources:
- [Kintara and TuHURA Merger Details](https://www.kintara.com/news/2024/kintara-therapeutics-and-tuhura-biosciences-enter-into-definitive-merger-agreement)
- [Capitol Trades on Laurel Lee's Investment](https://www.capitoltrades.com/politicians/L000597)
- [CohBar and Morphogenesis Merger Failure](https://www.marketwatch.com/story/cohbar-and-morphogenesis-abandon-merger-plan-amid-shareholder-rejection-11697196375)
$HURA It seems that the merger between $CWBR and Morphogenesis fell apart due to strategic mismatches and shareholder resistance. CohBar's focus on mitochondrial therapies didn't align well with Morphogenesis' oncology innovations, leading to operational and financial uncertainties.
In contrast, Kintara's merger with TuHURA benefits from a unified focus on cancer treatment and better financial planning, providing a more solid foundation for success.
$CWBR interesting !
had a notice to delist if no appeal by nov29,2023. clearly appealed but no PR.
Merger gave 15m runway with 6m burn per quarter means they are still going
Obesity NASH drug with OK results from a ph1...
then doing digging into the merger the company rebranded into Thura who JUST announced 31m deal with $HURA
